Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Saved in:
| Title: | Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. |
|---|---|
| Authors: | Gilan O; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Rioja I; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Knezevic K; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Bell MJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Yeung MM; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Harker NR; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Lam EYN; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Chung CW; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Bamborough P; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Petretich M; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Urh M; Promega Corporation, Madison, WI, USA., Atkinson SJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Bassil AK; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Roberts EJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Vassiliadis D; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Burr ML; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Preston AGS; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Wellaway C; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Werner T; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Gray JR; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Michon AM; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Gobbetti T; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Kumar V; Computational Biology, GlaxoSmithKline, Collegeville, PA, USA., Soden PE; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Haynes A; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Vappiani J; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Tough DF; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Taylor S; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Dawson SJ; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Bantscheff M; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Lindon M; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Drewes G; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Demont EH; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Daniels DL; Promega Corporation, Madison, WI, USA., Grandi P; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Prinjha RK; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK. mark.dawson@petermac.org rabinder.prinjha@gsk.com., Dawson MA; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. mark.dawson@petermac.org rabinder.prinjha@gsk.com.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia. |
| Source: | Science (New York, N.Y.) [Science] 2020 Apr 24; Vol. 368 (6489), pp. 387-394. Date of Electronic Publication: 2020 Mar 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1095-9203 |
|---|---|
| DOI: | 10.1126/science.aaz8455 |
